Contarato Jonad L A, Barbalho Geisa N, Cunha-Filho Marcilio, Gelfuso Guilherme M, Gratieri Tais
Laboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasília, Brasília 72220-275, DF, Brazil.
Gels. 2024 Aug 20;10(8):538. doi: 10.3390/gels10080538.
The OphthalMimic is a 3D-printed device that simulates human ocular conditions with artificial lacrimal flow, cul-de-sac area, moving eyelid, and a surface to interact with ophthalmic formulations. All tests with such a device have used a continuous artificial tear flow rate of 1 mL/min for 5 min. Here, we implemented protocol variations regarding the application time and simulated tear flow to increase the test's discrimination and achieve reliable performance results. The new protocols incorporated the previously evaluated 0.2% fluconazole formulations containing or not chitosan as a mucoadhesive component (PLX16CS10 and PLX16, respectively) and novel moxifloxacin 5% formulations, either in a conventional formulation and a microemulsion (CONTROL and NEMOX, respectively). The flow rate was reduced by 50%, and a pre-flow application period was also included to allow formulation interaction with the membrane. The OphthalMimic model was used with both polymeric and hydrogel-based hybrid membranes, including a simulated eyelid. Lowering the flow made it feasible to prolong the testing duration, enhancing device discrimination potential. The hydrogel membrane was adequate for testing nanostructure formulations. The OphthalMimic device demonstrated once again to be a versatile method for evaluating the performance of ophthalmic drug formulations with the potential of reducing the use of animals for experimentation.
OphthalMimic是一种3D打印设备,可通过人工泪液流动、泪囊区、活动眼睑以及与眼科制剂相互作用的表面来模拟人类眼部状况。使用该设备进行的所有测试均采用1 mL/分钟的连续人工泪液流速,持续5分钟。在此,我们对应用时间和模拟泪液流动实施了方案变更,以提高测试的区分度并获得可靠的性能结果。新方案纳入了先前评估的含或不含作为粘膜粘附成分的壳聚糖的0.2%氟康唑制剂(分别为PLX16CS10和PLX16)以及新型5%莫西沙星制剂,分别为传统制剂和微乳剂(分别为CONTROL和NEMOX)。流速降低了50%,还包括预流动应用期,以使制剂与膜相互作用。OphthalMimic模型与聚合物和水凝胶基混合膜一起使用,包括模拟眼睑。降低流速使得延长测试持续时间成为可能,增强了设备的区分潜力。水凝胶膜适用于测试纳米结构制剂。OphthalMimic设备再次证明是一种评估眼科药物制剂性能的通用方法,具有减少动物实验使用的潜力。